Xanthomatous Dermal Changes in a Patient With Locally Advanced Basal Cell Carcinoma Treated Using Vismodegib. Am J Dermatopathol 2021 Aug 01;43(8):585-587
Date
02/04/2021Pubmed ID
33534208DOI
10.1097/DAD.0000000000001849Scopus ID
2-s2.0-85112126051 (requires institutional sign-in at Scopus site)Abstract
Basal cell carcinoma (BCC) is the most commonly diagnosed cutaneous cancer in the United States with more than 2.5 million treated annually. Genetic studies have revealed that approximately 90% of BCCs have a mutation in the hedgehog-signaling pathway. Patients with BCC usually have an excellent prognosis with surgical modalities, however, patients with locally advanced BCC may potentially experience significant cosmetic or functional impairment, with only surgical intervention. Vismodegib is a hedgehog pathway inhibitor that has been successful in treating patients with locally advanced BCC. We report a patient with BCC with a good response to vismodegib and a novel xanthomatous change in the excision specimen.
Author List
Smith SDB, Clarke CN, Clark MA, Harker-Murray AK, Sokumbi OAuthors
Melanie A. Clark MD Associate Professor in the Dermatology department at Medical College of WisconsinCallisia N. Clarke MD Chief, Associate Professor in the Surgery department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
AgedAnilides
Antineoplastic Agents
Carcinoma, Basal Cell
Humans
Male
Neoplasms, Second Primary
Pyridines
Skin Neoplasms
Xanthomatosis
